143 related articles for article (PubMed ID: 35435809)
1. Accuracy of publicly-listed locator information for buprenorphine waivered practitioners and opioid treatment programs in the US, 2020.
Barenie RE; Winbigler BL; Heidel RE; Wheeler JS
Subst Abus; 2022; 43(1):999-1003. PubMed ID: 35435809
[No Abstract] [Full Text] [Related]
2. Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics.
Nguyen T; Andraka-Christou B; Bradford WD; Simon K
J Addict Med; 2022 May-Jun 01; 16(3):e197-e202. PubMed ID: 34669615
[TBL] [Abstract][Full Text] [Related]
3. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
4. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
5. Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status.
Sanmartin MX; Ali MM; Dwyer DS
Subst Abus; 2022 Dec; 43(1):1072-1074. PubMed ID: 35442126
[No Abstract] [Full Text] [Related]
6. Supply of buprenorphine waivered physicians: the influence of state policies.
Stein BD; Gordon AJ; Dick AW; Burns RM; Pacula RL; Farmer CM; Leslie DL; Sorbero M
J Subst Abuse Treat; 2015 Jan; 48(1):104-11. PubMed ID: 25218919
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.
Auty SG; Stein MD; Walley AY; Drainoni ML
J Subst Abuse Treat; 2020 Aug; 115():108032. PubMed ID: 32600629
[TBL] [Abstract][Full Text] [Related]
8. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
Andrilla CHA; Moore TE; Patterson DG; Larson EH
J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
Krawczyk N; Jent V; Hadland SE; Cerdá M
J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
[TBL] [Abstract][Full Text] [Related]
10. Medicaid participation among practitioners authorized to prescribe buprenorphine.
Saunders H; Britton E; Cunningham P; Saxe Walker L; Harrell A; Scialli A; Lowe J
J Subst Abuse Treat; 2022 Feb; 133():108513. PubMed ID: 34148758
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
12. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
[TBL] [Abstract][Full Text] [Related]
13. The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.
Klein TA; Hartung D; Markwardt S
Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):5. PubMed ID: 35101077
[TBL] [Abstract][Full Text] [Related]
14. The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.
Stringfellow EJ; Lim TY; Dong H; Zhang Z; Jalali MS
Addiction; 2023 Nov; 118(11):2215-2219. PubMed ID: 37434347
[TBL] [Abstract][Full Text] [Related]
15. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
16. County-level Factors and Treatment Access Among Insured Women With Opioid Use Disorder.
Leech AA; McNeer E; Stein BD; Richards MR; McElroy T; Dupont WD; Patrick SW
Med Care; 2023 Dec; 61(12):816-821. PubMed ID: 37199507
[TBL] [Abstract][Full Text] [Related]
17. Barriers to accessing opioid agonist therapy in pregnancy.
Bedrick BS; O'Donnell C; Marx CM; Friedman H; Carter EB; Stout MJ; Kelly JC
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100225. PubMed ID: 33345932
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.
Stopka TJ; Babineau DC; Gibson EB; Knott CE; Cheng DM; Villani J; Wai JM; Blevins D; David JL; Goddard-Eckrich DA; Lofwall MR; Massatti R; DeFiore-Hyrmer J; Lyons MS; Fanucchi LC; Harris DR; Talbert J; Hammerslag L; Oller D; Balise RR; Feaster DJ; Soares W; Zarkin GA; Glasgow L; Oga E; McCarthy J; D'Costa L; Chahine R; Gomori S; Dalvi N; Shrestha S; Garner C; Shadwick A; Salsberry P; Konstan MW; Freisthler B; Winhusen J; El-Bassel N; Samet JH; Walsh SL
JAMA Netw Open; 2024 Feb; 7(2):e240132. PubMed ID: 38386322
[TBL] [Abstract][Full Text] [Related]
19. Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder.
Anyanwu P; Varisco TJ; Wanat MA; Bapat S; Claborn K; Thornton JD
J Pain Palliat Care Pharmacother; 2022 Jun; 36(2):103-111. PubMed ID: 35648731
[TBL] [Abstract][Full Text] [Related]
20. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
